ImmuDyne Signs Exclusive License Agreement for Clinically-Backed Solar Purpura Product
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of Over-the-Counter healthcare products, is pleased to announce the signing of an exclusive license to commercialize the patented Purpurex® product line.
Purpurex® is the first and only treatment for solar purpura (commonly referred to as “Senile Purpura”), a skin condition affecting over 8 million people in the US and 12% of people over the age of 50 worldwide. Purpurex® is a nutraceutical formulation comprised of bruise fighting supplements that work synergistically to reduce the appearance of Senile Purpura.
“Until now, no effective treatments have been available to address Senile Purpura. I believe Purpurex could become the leading brand in this market and am thrilled to collaborate with ImmuDyne’s experienced marketing professionals,” said leading dermatologist, Dr. Joshua M. Berlin.
Dr. Berlin was one of the lead authors who conducted a placebo-controlled, double-blind clinical trial to test the effects of Purpurex® on Senile Purpura patients. The study showed that those taking Purpurex® saw a 50% reduction in purpura lesions.
“We were drawn to the impressive clinical data Purpurex has shown and believed it would be a great fit for our marketing platform,” stated Justin Schreiber, President & CEO of Immudyne. “Branding, positioning and business development efforts for Purpurex are underway and we look forward to a successful product launch later this year.”
lmmuDyne, Inc. (the "Company") is an online direct response marketing company that builds innovative and proprietary health and wellness brands that seeks to transform and enrich the lives of consumers around the world. Immudyne’s scalable and global advertising technology infrastructure leverages the world’s largest social media and online sales platforms (Facebook, Google & Amazon) to rapidly and profitably grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.immudyne.com or email us at firstname.lastname@example.org.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, among other thing, statements regarding the offering, the expected gross proceeds, the expected use of proceeds and the expected closing of the offering. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell its products; the expected benefits and efficacy of the Company's products; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
Released March 28, 2018